The research, led by Junyu Lin, Zichang Ma, Yuxi Tao, and colleagues at the Fifth Affiliated Hospital of Sun Yat-sen University in Zhuhai, with corresponding author Yaqin Zhang, was built on a retrospective cohort of 288 patients with pathologically confirmed invasive breast cancer. Every patient had undergone preoperative dynamic contrast-enhanced magnetic resonance imaging, or DCE-MRI, the standard imaging technique that tracks how a gadolinium-based contrast agent flows into and washes out of breast tissue. Because tumors with lymphovascular invasion often show characteristic enhancement kinetics, aggressive contrast uptake followed by rapid washout, DCE-MRI contains subtle information about tumor biology that radiologists can only partially exploit. The team’s goal was to extract that information systematically using artificial intelligence.

The pipeline the researchers designed has two major stages. The first is automated tumor segmentation. Rather than relying solely on radiologists to manually trace tumor boundaries on each MRI slice, a laborious process subject to interobserver variability, the team trained a ResUNet++ network to perform the task automatically. ResUNet++ is an evolution of the widely used U-Net convolutional architecture for medical image segmentation, incorporating residual connections, attention blocks, and nested dense convolutions to improve boundary accuracy and small-structure capture. Its performance was strikingly consistent: the model achieved a Dice coefficient of 0.916 on the internal validation cohort and 0.921 on the external cohort, where the Dice score measures the spatial overlap between the automated segmentation and the manually delineated ground truth, with 1.0 representing perfect agreement. Scores above 0.9 are generally considered excellent for tumor segmentation tasks.

After segmentation, the system applies a boundary dilation of 4 millimeters around the automatically detected tumor region of interest, a deliberate technical choice that captures the peritumoral microenvironment. This matters because lymphovascular invasion occurs in the tissue immediately surrounding the tumor, where tumor cells invade vessel walls, so the peritumoral zone often carries stronger predictive signals than the tumor core itself. Within these dilated regions, the researchers extracted radiomic features, high-dimensional quantitative descriptors of texture, intensity distribution, shape, and spatial heterogeneity that human readers cannot perceive. In parallel, radiologists assessed conventional MRI features according to the BI-RADS criteria, the standardized Breast Imaging Reporting and Data System lexicon, providing a structured human interpretation layer.

The second stage is classification. The team constructed both single-modality models and a multimodal fusion network that integrates three complementary streams of information: the enhanced MRI images themselves, the radiomic features derived from the segmented tumor and its peritumoral region, and the BI-RADS-based semantic features assessed by radiologists. The classifier architecture is transformer-based, meaning it relies on self-attention mechanisms, the same core technology behind modern large language models. Self-attention allows the network to weigh the relationships among all parts of its input simultaneously rather than processing information only through local receptive fields, which is particularly well suited to capturing long-range spatial patterns within and around tumors and to reconciling heterogeneous feature types from different modalities. The final design used a two-stage multimodal classifier in which features are first refined within each modality before being fused.

The performance gains from multimodality were substantial. On the internal cohort of 238 patients, the two-stage multimodal model achieved an area under the receiver operating characteristic curve, or AUC, of 0.873, compared with 0.801 for the best single-modality transformer model. On the independent external cohort of 50 patients from outside the training distribution, the multimodal system scored 0.845 against 0.762 for the best unimodal model. The differences were statistically confirmed using the DeLong test, a standard nonparametric procedure for comparing correlated ROC curves. An AUC above 0.85 in an external, cross-center setting is a notable result for a prediction task of this kind, suggesting the model learned biologically meaningful patterns rather than idiosyncrasies of a single scanner or population.

Just as important as the accuracy is the system’s interpretability. Black-box predictions are a persistent obstacle to clinical adoption of medical AI, so the researchers applied two widely used explanation techniques. Grad-CAM, or Gradient-weighted Class Activation Mapping, generates heatmaps highlighting the image regions most influential in the network’s decision, allowing radiologists to verify that the model attends to tumor and peritumoral areas rather than artifacts. SHAP, which stands for SHapley Additive exPlanations, quantifies the contribution of each radiomic and clinical feature to individual predictions, drawing on game-theoretic Shapley value theory to distribute credit fairly among features. Together, these tools offer transparency into why the model flags a given tumor as likely to exhibit lymphovascular invasion.

The clinical implications could be significant. Currently, the gold standard for LVI assessment is postoperative histopathology using hematoxylin-eosin staining and immunohistochemical markers such as D2-40 and CD31 to visualize lymphatic and vascular endothelium. Because LVI status is only known after surgery, its influence on preoperative decision-making is indirect. Knowing a patient’s LVI risk beforehand could inform whether axillary lymph node dissection is warranted, whether sentinel lymph node biopsy alone is sufficient, whether neoadjuvant systemic therapy should be considered before surgery, and how aggressively to manage breast-conserving approaches. For patients identified as high-risk, clinicians could intensify surveillance and tailor adjuvant therapy planning.

The external validation deserves particular emphasis. Many promising AI models in radiology fail when moved to new hospitals because of differences in scanner manufacturers, imaging protocols, and patient demographics, a phenomenon often described as domain shift. Testing the model on 50 patients from a distinct cohort, while smaller in size, provides early evidence of generalizability across centers. The near-identical segmentation performance between internal and external data, 0.916 versus 0.921 Dice, and only a modest drop in classification AUC from 0.873 to 0.845, suggest the pipeline is reasonably robust to such variation. Still, the external cohort’s size means larger prospective multicenter trials will be needed before the system can be deployed in routine practice.

The study also illustrates a broader trend in medical imaging AI: the move toward fully automated end-to-end pipelines. By chaining automatic segmentation with multimodal transformer classification, the system removes a major bottleneck, the manual delineation of tumor regions, that has limited the scalability of earlier radiomics studies. Manual segmentation typically requires an experienced radiologist to spend twenty to thirty minutes per case, whereas the automated approach can process a scan in seconds, making population-scale screening and analysis feasible. The integration of BI-RADS semantic features alongside deep image features further shows how human expertise and machine perception can be combined, with the transformer architecture acting as a fusion engine that reconciles different levels of abstraction.

Funding for the work came from the National Natural Science Foundation of China, the Basic and Applied Basic Research Foundation of Guangdong Province, and the Zhuhai Basic and Applied Basic Research Project Foundation. The retrospective study was approved by the Medical Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University, with the requirement for individual informed consent waived given the retrospective use of routinely collected clinical data. The article is published open access under a Creative Commons license, and the team has shared supplementary material detailing the methods.

Breast cancer remains the most commonly diagnosed cancer in women worldwide, and lymphovascular invasion is a key element of prognostic staging across all major clinical guidelines, including those of the American Joint Committee on Cancer and the College of American Pathologists. A validated, automated, preoperative LVI predictor would add a genuinely new piece of information to the preoperative decision toolkit, one derived entirely from an imaging examination most breast cancer patients already undergo. If future prospective studies confirm the performance reported here, transformer-based multimodal analysis of DCE-MRI could become a routine companion to the radiologist’s report, quietly flagging the tumors whose behavior is more aggressive than their appearance suggests and helping ensure that surgical and systemic treatment decisions are made with the fullest possible picture of each patient’s disease.

The problem begins with the Response Evaluation Criteria in Solid Tumors, better known as RECIST—the internationally agreed rulebook that has governed how oncologists quantify tumor burden for decades. Under RECIST 1.1, radiologists select a small number of target lesions and track a single number for each: the longest diameter. A patient’s total tumor burden is thus compressed into a one-dimensional sum, with response categories defined by fixed thresholds, such as 30 percent shrinkage for a partial response. The scheme was celebrated for its reproducibility, but it flattens anatomy into a line. Tumors grow irregularly, cavitate, consolidate, or dissolve into scar tissue, and a diameter can remain deceptively stable while the mass behind it changes dramatically. The mismatch has grown more consequential with immunotherapy, which reshapes lesions in ways linear rules were never designed to capture. The survey highlights evidence that early tumor volume change on CT can predict pathological response and prognosis in non-small cell lung cancer patients receiving immunotherapy—an argument that volumetric assessment belongs at the center of response evaluation.

Turning volumetry from an aspiration into routine practice requires software that can delineate tumors without human tracing, and the engine of that capability is deep learning. The field’s foundational design is U-Net, introduced in 2015: an encoder–decoder architecture in which the encoder progressively compresses an image into abstract feature maps while the decoder expands them back into a voxel-by-voxel probability map marking tumor tissue. Its defining trick is the skip connection, which shuttles fine spatial detail from early encoder layers across the network bottleneck so that sharp boundaries survive compression. The three-dimensional extension, 3D U-Net, carried this logic to entire volumetric stacks, learning dense segmentation from sparse annotation—a natural fit for CT, where a tumor occupies a connected cluster of voxels across dozens of slices. Trained on expert-drawn contours with overlap-sensitive losses such as the Dice coefficient, these networks learn to separate malignant tissue from vessels, bronchi, pleura, and air. The clinical payoff is reproducibility: two radiologists handed the same scan will draw slightly different boundaries, while an algorithm returns the same contour every time.

From that foundation, the survey traces a decade of escalating sophistication. Attention mechanisms, popularized in medical imaging by Attention U-Net, force networks to suppress irrelevant anatomy and concentrate computational focus on suspicious regions, sharpening boundaries in the cluttered thoracic environment. UNet++ rebuilt the skip pathways as nested, densely connected branches that fuse features across multiple scales, better matching lesions ranging from sub-centimeter nodules to large invasive masses. Self-configuring frameworks such as nnU-Net automated the preprocessing and training choices that once demanded painstaking hand-tuning, and have become de facto baselines across segmentation benchmarks. Hybrid CNN–Transformer models such as TransUNet and Swin UNETR graft self-attention onto convolutional backbones: convolutions excel at local edges and textures, while attention layers relate distant patches of the image, supplying the long-range context needed for lobulated tumors sprawling across many slices. Multiscale, deeply supervised designs and recurrent residual variants were engineered specifically for lung tumors, and ensembles of 3D U-Nets have pushed nodule segmentation accuracy further. The survey organizes this crowded landscape by architecture, learning strategy, dataset, and intended clinical use, citing multicenter comparisons of Swin UNETR, nnU-Net, and TransUNet on lung tumor subtypes as evidence that architectural choice materially changes what a volume measurement is worth.

Anatomy alone, however, is not always decisive, and some of the most capable systems fuse CT with positron emission tomography. In PET/CT, the CT supplies structure while the PET signal reveals metabolism: malignant cells avidly consume a radioactive glucose analog, lighting up tumors whose borders are anatomically ambiguous. Multimodal networks exploit this pairing through spatial attention modules that learn, location by location, which modality to trust, recovering boundaries that either scan alone would blur. Beyond cleaner contours, the fusion yields metabolic volume biomarkers—measures such as metabolically active tumor volume that combine size with biological aggressiveness and have demonstrated value for risk stratification in non-small cell lung cancer. Publicly released whole-body FDG-PET/CT datasets with manually annotated tumor lesions, together with systematic benchmarks comparing architectures and training strategies on PET/CT volumes, are giving this multimodal branch of the field the standardized footing it long lacked.

None of this learning happens without data, and the survey pays sustained attention to the public resources anchoring the field. The Lung Image Database Consortium–Image Database Resource Initiative, known universally as LIDC-IDRI, remains the canonical repository for nodule detection, prized for its layered annotations from multiple radiologists. RIDER Lung CT occupies a different niche: it contains repeat scans of the same patients acquired minutes apart, the raw material for test–retest reproducibility studies that quantify how much apparent tumor change is biology versus measurement noise. NSCLC-Radiomics links CT-derived features to patient outcomes, enabling prognostic volumetric modeling. Yet each resource also exposes systemic weaknesses. Expert 3D annotation is slow and expensive, and radiologists genuinely disagree about tumor boundaries, especially where lesions abut the chest wall or blend into surrounding tissue; those disagreements propagate into training labels and, downstream, into the volumes being measured. Scanners, slice thicknesses, reconstruction kernels, and contrast protocols differ between hospitals, and models tuned to one acquisition style can falter on another—the domain-shift problem that shadows every medical AI deployment.

The survey’s central argument is that segmentation accuracy, however dazzling, is not the finish line; the question is whether the resulting volumes are stable enough to support clinical calls. Here, the evidence is accumulating. Multi-center, multi-observer reading studies of automated RECIST 1.1 and volumetric RECIST have found that machine-derived response assessments can rival the reliability of expert panels while removing much of the human variability. Volumetric CT growth-rate measurements have detected treatment effects in metastatic disease earlier than diameter-based criteria. In mesothelioma, where tumors wrap around the lung in shapes that defeat linear rules, fully automated deep learning volumetry has been validated against modified RECIST response criteria. In lung cancer specifically, early tumor volume change is being advanced as a novel CT indicator of pathological response and prognosis under immunotherapy, and volumetric measurements are being combined with radiomic texture features and blood biomarkers to anticipate pseudoprogression—the apparent growth that is actually immune-cell infiltration. Each of these advances rests on a segmentation mask a computer drew.

What separates these demonstrations from routine practice is a familiar list, which the authors dissect candidly. Annotated 3D datasets remain scarce relative to what deep learning craves, and annotation variability injects noise directly into the quantity clinicians hope to measure. Models are sensitive to scanner and acquisition protocol, so accuracy reported on one cohort rarely transfers unchanged to another. Interpretability is thin: a network offers no anatomical reasoning for the contour it draws, which complicates both clinician trust and regulatory approval. Multimodal integration—fusing CT with PET, clinical variables, and molecular data—remains technically immature. Most subtly, a high segmentation score does not guarantee volumetric reliability: a 5 percent apparent change in tumor volume between two scans may reflect boundary ambiguity rather than biology. Without test–retest validation and explicit uncertainty estimates, volumetric AI risks reproducing at scale the very inconsistency it was designed to eliminate.

The roadmap the authors chart is correspondingly forward-looking. Transformer-based volumetric models are expected to carry the architectural revolution that reshaped language processing into fully three-dimensional medical segmentation. Self-supervised and semi-supervised learning promise to exploit the enormous reservoir of unlabeled CT scans, teaching networks general lung anatomy before scarce expert contours are ever introduced—a direction embodied by recently reported lung CT foundation models trained on vast imaging collections for broad diagnostic use. Generative modeling could simulate tumor dynamics, synthesizing plausible growth and shrinkage sequences to augment scarce longitudinal data and train systems that predict response before it is visible. Perhaps most consequential for the clinic are uncertainty-aware systems that attach a confidence estimate to every contour, flagging cases where the algorithm is guessing so that human expertise is spent where it matters most. The authors also urge that volumetric biomarkers be validated against true clinical endpoints—pathological response, progression-free survival—rather than against segmentation scores, redefining success as decisions improved rather than pixels matched.

The stakes of getting this right are difficult to overstate. Global cancer statistics for 2022 place lung cancer among the most frequently diagnosed malignancies in the world and its deadliest, and low-dose CT screening programs are generating scan volumes that no human workforce can annotate the traditional way. If AI-driven volumetry matures, every follow-up scan could yield not a single diameter but a quantitative trajectory of tumor burden: earlier signals of response, earlier warnings of treatment failure, and measurements independent of which radiologist read the images. The Izmir survey is candid that the field stands closer to promise than to practice—the algorithms have largely learned to see, while medicine has not yet learned to trust. Closing that gap, the authors conclude, is less a computer-science problem than a clinical one, and the decisive experiments of the coming decade will unfold not in code repositories but in oncology wards, where a number that finally matches the true shape of a tumor could change what survival looks like.

Segmentation is the process of assigning a label to individual pixels or three-dimensional voxels in a medical scan. Instead of merely identifying that a tumor, organ or blood vessel is present, a segmentation model traces its precise boundaries. This information can be used to calculate tumor volume, measure organ shape, plan radiation treatment, guide surgery or monitor disease progression. Deep-learning systems typically learn this task from images paired with expert annotations, often called masks. During training, a neural network adjusts millions of internal parameters to reduce the difference between its predicted mask and the reference mask. The quality, consistency and diversity of those reference masks therefore directly influence what the model learns—and whether it can operate safely on images from a different hospital, scanner or patient population.

The researchers divide the benchmark ecosystem into five broad task scenarios. The first concerns segmentation of a single organ or tissue, such as the liver, brain, heart or retinal structures. The second focuses on lesion regions, including tumors and other abnormal areas. The third covers multiple organs or tissues within the same image, while the fourth addresses several lesion types or regions. The fifth combines multi-organ or multi-tissue segmentation with lesion detection and delineation. This classification matters because the computational difficulty changes substantially between tasks. A model that isolates one relatively uniform organ may face a very different problem from a system required to identify several organs, distinguish normal anatomy from lesions and preserve boundaries where tissues have similar intensity values.

The review’s dataset inventory spans multiple imaging modalities, including the familiar technologies of computed tomography and magnetic resonance imaging as well as other forms of clinical imaging. Each modality presents a different technical challenge. CT measures X-ray attenuation and often provides strong contrast for bone, lung and some abdominal structures, but exposes patients to ionizing radiation. MRI produces images through magnetic fields and radiofrequency signals, offering excellent soft-tissue contrast but often varying considerably with scanner strength, acquisition sequence and protocol. Ultrasound can capture images in real time, yet its appearance is affected by speckle noise, probe angle and operator technique. These differences create what machine-learning researchers call domain shift: a model trained on one distribution of images may lose accuracy when the image statistics change.

Benchmark datasets are intended to make algorithmic comparisons fair, but the survey shows why that goal is difficult to achieve. Datasets differ in image resolution, field of view, patient demographics, disease prevalence, annotation policy and the number of experts involved in labeling. Some contain only a small number of highly curated cases; others offer larger collections with less uniform annotations. A mask drawn by one radiologist may not match one drawn by another, particularly when a tumor boundary is indistinct or an organ is partially obscured. Even the definition of the target can vary. One study may label the visible tumor core, another the entire abnormal region and a third include surrounding tissue suspected of microscopic invasion. A model can therefore appear to perform differently not because its architecture changed, but because the task itself was defined differently.

Deep-learning segmentation is commonly assessed with overlap metrics such as the Dice similarity coefficient and intersection over union. The Dice score compares the overlap between the predicted region and the ground-truth region, doubling the shared area and dividing it by the total area of both regions. A score of one represents perfect agreement, whereas zero indicates no overlap. Intersection over union divides the shared area by the combined area and is more strongly penalized when the predicted and reference regions differ. Researchers may also report Hausdorff distance, which measures the greatest or near-greatest boundary discrepancy, and average surface distance, which captures how far the predicted contour lies from the reference contour. These metrics measure different aspects of performance: a high overlap score does not necessarily guarantee clinically acceptable boundaries, especially for small lesions where a few misplaced pixels can have major consequences.

The survey also highlights the problem of data leakage and overly optimistic evaluation. If images from the same patient, examination session or institution appear in both training and test sets, a model may exploit repeated visual patterns rather than learn general anatomical principles. Randomly splitting images is not always sufficient, because multiple slices from a single three-dimensional scan are highly correlated. More robust evaluation separates data at the patient level and, where possible, tests models on external datasets collected using different equipment or protocols. Without such safeguards, benchmark results may exaggerate how well an algorithm would function in clinical practice. A system that achieves impressive performance on a familiar dataset can still fail when confronted with motion artifacts, unusual anatomy, postoperative changes or a scanner it has never encountered.

The authors argue that the field’s next phase must move beyond simply collecting more images. Larger datasets are valuable, but scale alone cannot resolve incomplete demographic representation, inconsistent labeling or weak documentation. Future resources should record relevant information about patients, acquisition settings, annotation procedures and the provenance of each image while protecting privacy. Standardized labeling protocols and multiple expert annotations could make it possible to quantify uncertainty rather than treating one mask as an unquestionable truth. Privacy-preserving approaches, including de-identification, federated learning and carefully governed data-sharing frameworks, may help institutions collaborate without transferring raw patient records. Synthetic images and data augmentation can expand training diversity, but they must be validated carefully so that artificial examples do not introduce unrealistic anatomy or erase clinically important variation.

The dataset map could become a practical navigation tool for researchers developing the next generation of medical AI. By bringing together resources for organs, tissues, lesions and combined segmentation tasks, it offers a way to identify gaps, select more appropriate benchmarks and design evaluations that better reflect real-world use. The authors have also assembled a related online collection of medical segmentation datasets, intended to support continued exploration. The larger scientific significance is a shift in emphasis: progress should not be measured only by whether a new neural-network architecture raises a score on a familiar benchmark, but by whether it remains accurate, transparent and useful across hospitals, populations and imaging conditions. In medical imaging, the most powerful algorithm is not necessarily the one that wins a single leaderboard. It is the one whose performance survives contact with the messy biological and technological diversity of actual patients.

Subject of Research: Benchmark datasets for deep learning-based medical image segmentation

Article Title: A comprehensive review of benchmark datasets for deep learning-based medical image segmentation

Article References: Wang, A., Yang, C., Zhang, X. et al. “A comprehensive review of benchmark datasets for deep learning-based medical image segmentation.” Artificial Intelligence Review (2026). Original research article

Image Credits: AI Generated

DOI: 10.1007/s10462-026-11662-y

Keywords: medical image segmentation, deep learning, benchmark datasets, artificial intelligence, lesion segmentation, organ segmentation, medical imaging, dataset bias

Alzheimer’s disease is a progressive neurodegenerative disorder associated with memory loss, cognitive decline, and changes in behavior and daily functioning. Diagnosis is not based on a single test. Clinicians typically combine medical history, cognitive assessments, neurological examinations, laboratory investigations, and, in some cases, brain imaging or biomarker analysis. This multidimensional process can be difficult because early symptoms may overlap with normal aging or other forms of cognitive impairment. Artificial intelligence systems such as AlzheiNN are being developed to support this process by analyzing complex data and identifying combinations of features that may be too subtle, numerous, or time-consuming for routine manual evaluation.

The technology named in the study, a convolutional neural network, belongs to a class of deep learning systems particularly effective at recognizing structured patterns. Convolutional neural networks were originally popularized in image recognition, where they learn to detect visual features such as edges, shapes, textures, and increasingly complex arrangements. In medical research, these networks can be trained to examine brain scans, digitally represented clinical measurements, pathology images, or other forms of structured biological data. Instead of relying exclusively on rules designed by researchers, a CNN adjusts millions of internal numerical parameters during training so that its predictions increasingly correspond with labeled examples.

A typical CNN processes input through a sequence of mathematical operations known as convolutions. Small filters move across the input, calculating whether particular patterns appear in different locations. Early layers may identify simple structures, while deeper layers combine those signals into more informative representations. Pooling or downsampling operations can reduce the size of the data while preserving important features, and fully connected layers can use the resulting representation to assign a classification. In an Alzheimer’s disease application, the system might learn relationships among patterns associated with disease, healthy aging, or other cognitive conditions, depending on the design of the study and the information used for training. The architecture and training strategy determine how effectively the model generalizes beyond the examples it has already seen.

The name AlzheiNN combines Alzheimer’s disease with “neural network,” signaling the study’s emphasis on a specialized artificial intelligence model rather than a general-purpose clinical algorithm. The model’s significance will ultimately depend on several factors that are essential in medical machine learning: the size and diversity of the training dataset, the quality of the diagnostic labels, the type of input data, and the way the system was evaluated. A model can achieve impressive results on a limited or highly controlled dataset yet perform less reliably in hospitals serving different populations. For that reason, independent testing, external validation, and transparent reporting are as important as the initial classification score.

One of the most important technical issues in systems like AlzheiNN is the distinction between classification and diagnosis. A classifier identifies statistical similarities between an input and the categories represented in its training data. It does not independently establish the biological cause of a patient’s symptoms, replace a neurologist, or determine the most appropriate treatment. A clinically useful system would need to operate alongside professional judgment, offering evidence that can be reviewed rather than presenting an unexplained verdict. Researchers therefore examine measures such as sensitivity, specificity, precision, recall, area under the receiver operating characteristic curve, and calibration. These measures reveal different aspects of performance and help determine whether a model is suitable for screening, research support, or clinical decision-making.

Interpretability is another major concern. Deep neural networks can be highly accurate while remaining difficult to understand, a problem often described as the “black box” challenge. In Alzheimer’s research, clinicians may need to know which regions of a scan, which measurements, or which features influenced a prediction. Visualization methods, feature-importance analyses, and explanation techniques can provide clues, but these tools do not automatically prove that the model is using medically meaningful information. A network may accidentally learn technical artifacts, demographic differences, or characteristics of a particular dataset rather than disease-related biology. Robust studies must therefore test whether predictions remain stable when equipment, institutions, patient populations, and data-processing procedures change.

The broader appeal of automated classification lies in the possibility of earlier and more consistent assessment. If validated, an AI tool could help researchers screen large datasets, identify candidates for clinical studies, or prioritize cases for specialist review. It might also support the analysis of medical images and other data at a scale that would be difficult to achieve manually. However, the benefits would depend on careful integration into healthcare systems. Differences in scanner hardware, image protocols, electronic records, and patient demographics can all affect model performance. Privacy, informed consent, cybersecurity, and fairness must also be addressed, particularly when systems are trained on sensitive neurological and medical information.

The study by Paul, Manna, Singh and colleagues arrives as the scientific community continues to refine the role of artificial intelligence in neurodegenerative disease research. The field is moving beyond the question of whether a computer can identify patterns and toward more demanding questions: Can the system work across hospitals? Can it detect disease at an early stage? Does it provide information that changes clinical decisions? Can its predictions be explained and audited? Does it perform equitably across age groups, sexes, ethnic backgrounds, and levels of education? The citation for AlzheiNN establishes the model’s purpose and publication context, but detailed answers to these questions require examination of the full article, including its methods, datasets, validation procedures, and results.

AlzheiNN therefore represents a significant direction in contemporary Alzheimer’s research: the construction of computational models that may assist with the classification of a disease whose biological and clinical presentation is highly complex. Its contribution will be judged not only by how accurately it labels data, but also by how reliably it performs in real-world settings and how responsibly its predictions can be used. For now, the publication adds another entry to the expanding scientific effort to combine neuroscience, medical imaging, and deep learning. The promise is considerable, but the path from an experimental neural network to a trusted clinical tool will require transparency, independent replication, and evidence that artificial intelligence improves patient care rather than simply producing impressive numbers.

Subject of Research: Alzheimer’s disease classification using a convolutional neural network.

Article Title: AlzheiNN: a convolutional neural network-based model for Alzheimer’s disease classification.

Article References: Paul, R., Manna, A., Singh, L. et al. “AlzheiNN: a convolutional neural network-based model for Alzheimer’s disease classification.” Scientific Reports (2026). https://doi.org/10.1038/s41598-026-64954-2

Image Credits: AI Generated

DOI: 10.1038/s41598-026-64954-2

Keywords: Alzheimer’s disease, convolutional neural network, deep learning, artificial intelligence, disease classification, medical imaging, neural networks

Acute abdominal pain can arise from dozens of causes, ranging from self-limiting inflammation to internal bleeding, bowel obstruction, perforation or ischemia. Symptoms often overlap, while the patient’s condition can deteriorate quickly. CT imaging is central to emergency evaluation because it can reveal abnormalities that are not apparent from physical examination or laboratory tests alone. Yet many emergency departments face practical constraints, including limited access to contrast agents, concerns about kidney function or allergies, and the need to make decisions before a complete diagnostic work-up is available.

The model described in the study is built around noncontrast CT, an examination performed without injecting an iodinated contrast agent into the bloodstream. Contrast-enhanced scans can make blood vessels, organ perfusion and subtle areas of inflammation easier to see, but noncontrast imaging remains valuable when contrast is unsuitable or unavailable. Interpreting these scans is technically demanding because the algorithm must identify patterns based primarily on differences in tissue density, anatomy, shape and spatial relationships. A foundation model is intended to learn broad, reusable representations from large and varied datasets rather than being trained for only one narrowly defined diagnosis.

In medical artificial intelligence, this distinction is important. Traditional systems are often developed to answer a single question, such as whether appendicitis is present or whether a scan contains a fracture. A foundation model, by contrast, is designed as a general-purpose platform that can be adapted to multiple tasks. In the setting of acute abdominal imaging, that may include recognizing a range of abnormalities, estimating the seriousness of a case and helping sort patients according to the urgency of treatment. The approach could allow one model to support several stages of emergency decision-making instead of functioning as an isolated diagnostic tool.

Diagnosis stratification refers to organizing patients by the likely severity and clinical consequences of their condition. Triage adds an operational dimension: it helps determine who should be evaluated first, who may need urgent surgical consultation and who can proceed through a less immediate pathway. These decisions are not simply questions of naming a disease. They require an assessment of risk, uncertainty and time sensitivity. A patient with a relatively uncommon finding may still require immediate attention if delayed treatment could lead to organ damage or death.

The use of artificial intelligence in this setting could be especially relevant during periods of high emergency-department demand. A model capable of reviewing scans rapidly might help flag potentially dangerous findings for radiologists and emergency physicians, reducing the chance that a critical examination remains buried in a long queue. It could also provide a consistent preliminary assessment across hospitals with different levels of specialist availability. However, such a system would be most useful as a decision-support tool, not as an autonomous replacement for clinical judgment.

Noncontrast CT also presents a demanding test for algorithm developers. Some abdominal diseases are easier to recognize when contrast highlights abnormal blood flow, active bleeding or differences between healthy and diseased tissue. A model working without those signals must extract more information from the native appearance of organs and the surrounding abdominal structures. It must also cope with variations in scanner hardware, image quality, patient positioning, body size and the presence of unrelated abnormalities. These technical challenges make broad validation essential before an AI system can be safely used in routine emergency care.

The study’s significance therefore extends beyond the creation of another image-classification algorithm. It reflects a broader movement toward medical AI systems that combine detection, risk assessment and workflow support. For clinicians, the value of such a model will depend not only on whether it recognizes abnormalities, but also on how reliably it communicates uncertainty, how often it produces false alarms and whether its recommendations improve patient outcomes. A model that identifies more cases but overwhelms staff with unnecessary alerts may offer little practical benefit, while a system that misses time-critical disease could create serious harm.

Before widespread deployment, independent testing across hospitals, populations and imaging protocols will be necessary. Researchers will need to examine whether performance remains stable in older adults, children, patients with previous surgery and people whose symptoms do not fit typical patterns. Evaluation should also consider health equity, because differences in access to high-quality imaging and specialist review can affect both training data and real-world performance. Clear oversight, audit trails and mechanisms for clinicians to challenge an algorithmic recommendation will be central to responsible adoption.

The foundation model presented by Zhu and colleagues points toward a future in which emergency imaging systems do more than display pictures. They may help transform raw scans into timely estimates of clinical urgency, supporting faster coordination between radiology, emergency medicine and surgery. Yet the promise of rapid triage must be balanced with the complexity of abdominal disease and the limits of machine interpretation. The technology’s ultimate test will not be whether it can produce impressive predictions in a research setting, but whether it can help doctors make safer, faster and more equitable decisions for patients in the most critical hours of care.

Subject of Research: Artificial intelligence for acute abdomen diagnosis stratification and triage using noncontrast computed tomography

Article Title: A foundation model for acute abdomen diagnosis stratification and triage on noncontrast computed tomography

Article References: Zhu, C., Zhang, R., Song, X. et al. A foundation model for acute abdomen diagnosis stratification and triage on noncontrast computed tomography. Nature Communications (2026). https://doi.org/10.1038/s41467-026-76634-w

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76634-w

Keywords: Foundation model, acute abdomen, noncontrast computed tomography, medical artificial intelligence, diagnosis stratification, clinical triage

MRI’s unparalleled ability to detail complex anatomy across multiple sequences makes it indispensable for diagnosis. However, the variability intrinsic to these sequences introduces significant obstacles for artificial intelligence, limiting the models’ generalizability and often confining their application to narrow clinical contexts. MARS tackles this by employing a unique pretraining strategy that disentangles anatomy-invariant features from sequence-specific variations. This key innovation allows the model to learn robust, transferable representations that retain critical clinical information across diverse imaging conditions.

The team amassed an unprecedented dataset for pretraining MARS, gathering 336,476 volumetric scans from 34 datasets encompassing 10 different anatomical regions and multiple MRI sequences. These data were drawn from a blend of eight public and 26 private collections, forming a comprehensive multi-organ, multi-sequence corpus unparalleled in scale and diversity. Such extensive and heterogeneous input enables MARS to internalize the wide spectrum of MRI variability, bolstering its adaptability to real-world clinical scenarios.

To rigorously evaluate the model’s versatility, researchers established a benchmark suite encompassing 44 downstream tasks. These spanned a broad array of clinical functions: disease diagnosis, anatomical segmentation, spatial registration, disease progression prediction, and automated report generation. Demonstrating remarkable breadth, MARS secured the top ranking in 41 out of 44 challenges, often with statistically significant performance improvements over existing methods.

One of the most impressive aspects of MARS is its strong generalization capability, particularly when tested on external datasets that differ substantially from the pretraining data—a critical attribute for clinical translation. By capturing anatomy-invariant patterns, the model overcomes the idiosyncrasies introduced by varying MRI protocols, patient populations, and scanner technologies. This robustness paves the way for wider adoption of AI-driven MRI analysis tools in healthcare settings globally.

These findings have immediate implications for both clinical practice and future AI model development. MARS represents a scalable foundation potentially transformable into numerous diagnostic and prognostic applications, streamlining radiological workflows and elevating diagnostic accuracy. Moreover, the methodological framework of disentangling sequence-specific variation offers a blueprint for addressing similar heterogeneity challenges across other medical imaging modalities.

Looking ahead, the research community anticipates that MARS will catalyze innovation in multi-modal medical imaging and multimodal AI integration, driving forward precision medicine initiatives. By bridging the gap between big data in clinical imaging and generalizable machine learning models, this work marks a significant leap toward AI systems capable of comprehensive, real-world medical image interpretation.

As healthcare increasingly embraces AI-driven diagnostics, MARS stands out as a pioneering example of how large-scale, heterogeneous data combined with sophisticated model design can surmount longstanding challenges, promising to reshape the future landscape of medical imaging analysis.

Subject of Research: Multi-sequence MRI analysis using large-scale deep learning foundation models for clinical applications.

Article Title: Large-scale multi-sequence pretraining for generalizable MRI analysis in versatile clinical applications.

Article References:
Qiu, Z., Wang, X., Xie, Z. et al. Large-scale multi-sequence pretraining for generalizable MRI analysis in versatile clinical applications. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01740-5

DOI: https://doi.org/10.1038/s41551-026-01740-5

Chest radiography remains one of the most common diagnostic procedures worldwide, indispensable in screening and evaluating respiratory diseases such as pneumonia, tuberculosis, lung cancer, and heart-related anomalies. However, conventional interpretation heavily depends on radiologists’ expertise, with significant variability influenced by training, fatigue, and workload. DeepSeek addresses these challenges by employing a robust convolutional neural network architecture that mimics human visual cognition, offering consistent, objective, and reproducible assessments of radiographic images across diverse patient populations.

At the core of DeepSeek’s functionality lies its vast training dataset, comprising millions of annotated radiographs sourced from multinational healthcare centers. This extensive compilation enables the AI to learn subtle radiographic patterns that often elude human observers, especially in early disease stages. The system applies hierarchical feature extraction techniques, progressively refining its understanding from pixel-level anomalies to complex pathophysiological signatures, thus enhancing diagnostic sensitivity and specificity.

Beyond mere detection, DeepSeek offers comprehensive radiograph interpretation, including the localization and characterization of pathological findings. Utilizing advanced attention mechanisms, the system highlights regions of interest within the radiograph, providing visual explainability to clinicians and fostering trust in AI-derived insights. This interpretability is pivotal in clinical practice, ensuring radiologists can validate AI suggestions and incorporate them prudently into patient management strategies.

The integration of DeepSeek into electronic health records and picture archiving systems facilitates seamless workflow synchronization, reducing diagnostic turnaround times. Clinical trials implementing DeepSeek in hospital settings demonstrated a substantial increase in reporting efficiency, enabling radiologists to focus on complex cases while routine assessments are reliably automated. The system’s adaptability further allows customization to meet institution-specific protocols and prevalence patterns, reinforcing its versatility across healthcare environments.

One of the most compelling aspects of DeepSeek is its potential to alleviate healthcare disparities, particularly in underserved regions with limited access to radiology expertise. The AI model, deployed via cloud infrastructure, empowers remote clinics to obtain expert-level radiograph interpretations instantaneously. This democratization of diagnostic services could significantly enhance early disease detection rates, guiding timely interventions and improving prognostic outcomes in resource-constrained settings.

The architecture of DeepSeek also incorporates continuous learning capabilities, allowing the AI to assimilate new clinical data and evolving diagnostic criteria dynamically. This adaptive learning mechanism ensures sustained performance enhancement, accommodating emerging disease manifestations and incorporating clinician feedback. Such a feedback loop is instrumental in maintaining the AI system’s relevance and accuracy amid the dynamic landscape of medical knowledge.

Additionally, the system’s robustness against image quality variability, differing radiograph machines, and patient positioning is achieved through extensive data augmentation and normalization techniques during training. Consequently, DeepSeek delivers consistent interpretations regardless of technical inconsistencies, an indispensable characteristic for real-world clinical deployment where image acquisition conditions vary widely.

From a regulatory and ethical perspective, DeepSeek’s developers have emphasized transparency, patient privacy, and compliance with global healthcare standards. Rigorous validation studies underpin the system’s FDA clearance and CE marking, asserting its safety and efficacy for clinical use. Moreover, patient data anonymization protocols and secure data handling frameworks underpin the AI’s trustworthy integration into medical infrastructures.

Clinical adoption studies reveal that DeepSeek not only streamlines workflows but also enhances diagnostic accuracy when used in conjunction with human expertise, mitigating error rates and augmenting radiologist confidence. Such synergistic human-AI collaboration is foreseen as the optimal paradigm, balancing technological innovation with clinical judgment to achieve superior healthcare outcomes.

Furthermore, DeepSeek’s potential extends beyond chest radiographs to other imaging modalities such as CT scans and MRI, with ongoing research exploring modular extensions of the system’s architecture. This scalability promises a comprehensive AI suite capable of holistic radiological evaluation, further cementing AI’s role as a cornerstone of future medical diagnostics.

The system’s impact also reverberates in medical education and training, where DeepSeek serves as an interactive tool for medical students and residents to understand radiographic pathology more concretely. By providing instant feedback and visual annotations, the AI accelerates learning curves and cultivates diagnostic acumen from early stages of medical careers.

In light of these multifaceted benefits, DeepSeek epitomizes the merging of artificial intelligence and medicine, heralding a paradigm shift in how clinicians interpret radiographic data. As healthcare systems worldwide grapple with increasing demand and workforce shortages, AI solutions like DeepSeek offer hope for sustainable, high-quality patient care accessible to all.

Looking ahead, the research team intends to expand DeepSeek’s capabilities to encompass prognosis prediction and therapeutic response assessment, incorporating multimodal patient data including clinical notes and laboratory results. Such integrative AI approaches could usher in precision medicine models, tailoring treatments based on comprehensive data analytics.

Ultimately, DeepSeek exemplifies the transformative potential of artificial intelligence in medical imaging, illustrating how cutting-edge technology can augment human expertise without supplanting it. This harmonious collaboration between human and machine promises to redefine diagnostic medicine, making it more efficient, equitable, and insightful for a new generation of healthcare.

Subject of Research: Automated chest radiograph interpretation using AI-powered deep learning systems in clinical practice.

Article Title: A DeepSeek-powered AI system for automated chest radiograph interpretation in clinical practice.

Article References:
Bai, Y., Zhang, R., Lei, Y. et al. A DeepSeek-powered AI system for automated chest radiograph interpretation in clinical practice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72680-6

Image Credits: AI Generated

Traditionally, BMI and simple body weight measurements have served as the cornerstone metrics for estimating health risks related to cardiovascular and metabolic disorders. However, BMI’s inherent limitations—primarily its failure to differentiate between muscle mass and fat or their respective anatomical distributions—have prompted a search for better indicators. This new research confronts that gap head-on by employing deep learning algorithms capable of dissecting complex MRI data to precisely quantify subcutaneous fat, visceral adipose tissue, skeletal muscle volume, intramuscular fat, and muscle quality.

The study cohort, drawing from the extensive UK Biobank and German National Cohort, encompasses 66,608 participants with a mean age approaching 58 years. Their body composition metrics were normalized for age, sex, and height, yielding z-scores that represent individual deviation from population-adjusted norms. This normalization is crucial to accurately gauge risk, as muscle and fat distribution naturally fluctuate throughout the lifespan and differ markedly between sexes and body sizes.

One of the critical revelations from this research highlights that visceral fat—fat stored around internal organs—is associated with a 2.26-fold increased risk of developing diabetes. This finding reaffirms the pathogenic role of visceral adiposity but importantly places it within a framework of nuanced risk assessment informed by personalized body composition profiles rather than crude BMI scores.

Equally transformative is the insight into muscle quality and quantity. High levels of intramuscular fat, indicative of poor muscle quality, correlated with a 1.54-fold increased risk of major cardiovascular events. Meanwhile, a low skeletal muscle mass independently predicted a 1.44-fold higher risk of all-cause mortality, underscoring muscle not just as a mechanical structure but as a vital metabolic organ whose integrity impacts survival beyond traditional cardiometabolic risk factors.

These findings challenge the medical community to rethink how patient risk profiles are constructed and suggest that future clinical protocols might incorporate automated AI-driven imaging tools to routinely assess muscle and fat parameters during standard imaging exams. The AI framework developed for this study is open-source and fully automated, able to extract precise body composition metrics from whole-body MRI scans with minimal human intervention, enhancing reproducibility and clinical scalability.

From a technical perspective, the research team leveraged convolutional neural networks trained on massive annotated datasets to segment and quantify multiple tissue compartments. This approach surpasses older techniques like dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA), which cannot discern intramuscular fat fractions or provide detailed anatomical fat distributions with high accuracy.

The study also generated reference curves that map body composition trajectories throughout the aging process, stratified by sex and height. Such standardized references are invaluable not only for risk stratification but also for monitoring therapeutic interventions, enabling clinicians to differentiate between beneficial fat loss and detrimental muscle wasting, particularly relevant in contexts like weight-loss treatments utilizing GLP-1 receptor agonists.

Importantly, this novel AI-powered analytical framework can apply to a range of existing imaging modalities beyond dedicated whole-body MRI scans. Routine chest or abdominal CTs and MRIs, commonly acquired in clinical practice, harbor untapped data on muscle and fat composition that, with this technology, can be extracted and harnessed for improved patient care without additional imaging burden.

The implications extend beyond metabolic and cardiovascular medicine. The capability to finely characterize body composition holds promise for oncology, where muscle loss (sarcopenia) and fat distribution influence treatment toxicity, survival outcomes, and cancer recurrence. Validating these reference standards in clinical populations forms the next frontier of this research, fine-tuning diagnostic tools tailored for diverse disease contexts.

This research signifies a pivotal shift toward precision medicine driven by data-rich, AI-enabled imaging analytics. It propels the medical field toward a future where personalized body composition metrics will be seamlessly integrated into routine diagnostics, facilitating earlier detection of risk, more informed treatment decisions, and personalized monitoring of disease progression and therapy response.

By turning the hidden layers of everyday imaging data into actionable clinical insights, the study paves the way for a new paradigm in health care—one that recognizes the multifaceted nature of body composition as a critical determinant of overall health and disease risk, beyond the simplistic measures of weight and height.

Subject of Research:
People

Article Title:
Body Composition in the General Population: Whole-body MRI-derived Reference Curves from Over 66,000 Individuals

News Publication Date:
5-May-2026

Web References:
– Radiology Journal: https://pubs.rsna.org/journal/radiology
– Radiological Society of North America: https://www.rsna.org/
– Patient Information on MRI: http://www.radiologyinfo.org

Keywords:
Artificial intelligence, Body size, Imaging, Magnetic resonance imaging, Diabetes, Cardiovascular disorders

In response to these challenges, a groundbreaking deep learning framework named Residual-Guided Spatiotemporal Transformer Graph Fusion (RST2G) has been developed to revolutionize breast tumor segmentation within DCE-MRI imaging. This innovative approach synergistically integrates residual learning mechanisms, hybrid feature extraction strategies, and the fusion of spatiotemporal graph representations. The design is meticulously tailored to leverage DCE-MRI’s multifaceted temporal and spatial data, combining pre-contrast and multiple post-contrast phases, enabling a more nuanced understanding of tumor vascular dynamics and tissue heterogeneity than conventional methods.

At the heart of RST2G lies the CFormerEncoder, a hybrid feature extractor that blends convolutional neural networks with transformer-based architectures. This amalgamation allows the model to capture both local fine-grained details and long-range dependencies across the volumetric and temporal dimensions of DCE-MRI data. The integration of residual-guided multi-scale refinement modules further enhances the model’s ability to resolve subtle and complex tumor boundaries by iteratively refining feature maps and preserving crucial anatomical detail. This refinement is bolstered by a unique spatiotemporal graph fusion component that models dynamic interactions between tissue regions over time, effectively synthesizing signal changes that signify tumor progression or response.

To validate their model, the researchers applied RST2G to two robust publicly available DCE-MRI datasets. The Breast-MRI-NACT-Pilot dataset comprises 64 patients undergoing neoadjuvant chemotherapy, encompassing multi-phase contrast scans that illuminate treatment-induced morphological changes. The TCGA-BRCA cohort, with 139 patients and extended post-contrast imaging, offered a substantial and diverse testbed representing various tumor phenotypes and contrast kinetics. Across these datasets, RST2G demonstrated striking performance gains, with Dice Similarity Coefficients reaching 61.8% and 80.1%, respectively, substantially surpassing traditional U-Net variants and 3D volumetric models.

Beyond segmentation accuracy, the model excelled in minimizing relative volume difference (RVD), achieving near-ideal tumor volume quantification—critical for accurate treatment monitoring and prognosis assessment. Importantly, RST2G maintained strong generalization capabilities on external datasets acquired from clinical centers with distinct imaging protocols, underscoring its robustness and potential for real-world clinical adaptability. Visualizations produced using Grad-CAM techniques confirmed that the residual-guided attention mechanisms homed in on pathologically relevant tumor regions and boundaries, offering interpretability and fostering clinician confidence in the automated outputs.

The implications of RST2G’s success extend far beyond mere segmentation metrics. By automating tumor delineation in DCE-MRI, the framework alleviates the considerable workload burden on radiologists and reduces inter-observer variability, which has historically plagued precision oncology workflows. Accurate and consistent tumor boundary definition facilitates precise volumetric measurement, essential for planning surgical interventions and evaluating neoadjuvant chemotherapy efficacy. Moreover, the ability to capture spatiotemporal tumor dynamics opens new avenues for personalized treatment strategies and longitudinal disease monitoring.

Technically, RST2G is designed with clinical translation in mind. The entire processing pipeline can segment a full MRI volume in approximately 30 seconds using a standard 10 GB GPU, making near-real-time deployment feasible in busy radiology departments. This computational efficiency stems from the model’s hybrid transformer-graph architecture, which harnesses the parallelization strengths of attention mechanisms while mitigating computational overhead via graph fusion techniques. Such efficiency is pivotal in integrating AI-assisted tools seamlessly into established clinical imaging workflows.

Looking ahead, the research team aims to rigorously validate RST2G across multi-center cohorts to ensure robustness against heterogeneous imaging protocols, scanner types, and patient populations—a critical step for regulatory approval and widespread adoption. Another exciting frontier lies in adapting the model to irregular temporal sampling inherent in DCE-MRI acquisitions, enabling flexible analysis regardless of varying post-contrast scan timings. Integration with clinical decision-support systems is also planned to deliver actionable information directly to oncologists and multidisciplinary teams, thus advancing personalized breast cancer care.

In essence, RST2G represents a paradigm shift in automated breast tumor segmentation by explicitly modeling the complex spatiotemporal trajectories of contrast agent dynamics in DCE-MRI. Its novel fusion of residual learning, hybrid feature extraction, and graph-based temporal modeling surmounts previous limitations encountered by conventional networks. As a result, the framework offers unprecedented accuracy, interpretability, and clinical readiness, promising to transform how breast cancer imaging data is analyzed and leveraged for therapeutic decision-making.

The authors of this innovative study assert that by enhancing segmentation precision and consistency, RST2G addresses an urgent unmet need, facilitating more reliable assessments of tumor morphology and treatment response in clinical practice. This breakthrough technique not only holds promise for improving diagnostic workflows but also serves as a foundational platform upon which future AI-driven imaging innovations can be built.

—
Subject of Research: Breast cancer tumor segmentation in Dynamic Contrast-Enhanced MRI using deep learning
Article Title: RST2G: Residual-Guided Spatiotemporal Transformer Graph Fusion Enhancement for Breast Cancer Segmentation in DCE-MRI
News Publication Date: March 23, 2026
Web References: https://doi.org/10.34133/cbsystems.0502
Image Credits: Maoshan Chen, Department of Breast and Thyroid Surgery, Suining Central Hospital

Keywords

Breast Cancer, Tumor Segmentation, DCE-MRI, Deep Learning, Spatiotemporal Modeling, Residual Learning, Transformer Networks, Graph Fusion, Medical Imaging, AI in Healthcare, Oncology, Neural Networks

Traditional cardiovascular risk prediction has relied heavily on a combination of clinical factors such as age, sex, blood pressure, cholesterol levels, and diabetes status, coupled with imaging techniques like coronary artery calcium (CAC) scoring. CAC scoring quantifies the extent of calcified plaque deposits within coronary arteries and has been a staple in routine cardiovascular evaluations for many years. Despite its utility, CAC has limitations, particularly in stratifying risk among patients who fall into borderline or intermediate categories. This is where the Mayo Clinic study’s innovation shines, by augmenting CAC assessments with AI-driven analysis of pericardial adipose tissue—the fat surrounding the heart.

The research team applied deep learning algorithms to electrocardiogram-gated cardiac computed tomography (CT) scans of nearly 12,000 adults, performed over a span of approximately 16 years. Unlike traditional manual measurements, AI enabled rapid, automated quantification of pericardial fat volume, ensuring consistency and reproducibility at scale. This task, which had previously been cumbersome and variable, was revolutionized by AI’s capacity to sift through imaging data with unprecedented precision, extracting nuanced information beyond simple calcium scoring.

Crucially, the volume of pericardial fat emerged as an independent predictor of cardiovascular events, including heart attacks and strokes, even after adjusting for established risk factors and CAC scores. This finding challenges the conventional understanding that focuses predominantly on coronary calcification and highlights the metabolic and inflammatory nuances that pericardial adipose tissue may signify. The accumulation of fat around the heart is increasingly recognized as a dynamic factor influencing coronary artery disease through local inflammatory processes and its impact on myocardial function.

Integration of pericardial fat measurements with standard risk equations like the American Heart Association’s PREVENT model considerably improved the accuracy of long-term cardiovascular risk predictions. The combined model demonstrated heightened discriminatory power especially among patients stratified as low or intermediate risk based on traditional assessments. This precision medicine approach offers clinicians a powerful new tool to tailor preventative strategies, potentially initiating earlier interventions for those who may otherwise be overlooked.

One of the most compelling aspects of the study is that it leverages imaging already performed as part of routine clinical care, eliminating the need for additional tests, radiation exposure, or costs. Coronary CT scans, being widely adopted in clinical settings, now serve a dual purpose: traditional calcium scoring and AI-enhanced quantification of cardiac fat. This novel methodology is not only practical but scalable, paving the way for wide dissemination and immediate clinical impact.

The lead researcher, Zahra Esmaeili, emphasized the transformative potential of this approach. The automatic and precise measurement of pericardial fat can help augment the clinical decision-making process where ambiguities exist, particularly for patients on the threshold of risk categories. By delivering more detailed patient-specific risk profiles, healthcare providers can advance towards more personalized and effective cardiovascular disease prevention.

Senior author Francisco Lopez-Jimenez, director of the AI in Cardiology program at Mayo Clinic, underscored the synergy between cutting-edge AI techniques and traditional cardiovascular diagnostics. This collaboration promises to revolutionize screening and preventative cardiology by enabling clinicians to identify subtle yet meaningful indicators of disease earlier in the pathological trajectory, ultimately reducing the burden of cardiovascular morbidity and mortality.

Throughout the longitudinal study, nearly 10% of participants developed cardiovascular disease, reinforcing the persistent threat imposed by heart disease worldwide. Notably, individuals with the highest volumes of pericardial fat faced elevated risks regardless of their coronary calcium burden, suggesting that pericardial fat quantification captures distinct biological signals with profound prognostic importance.

The study not only augments the existing scientific knowledge on cardiac adiposity’s role in coronary artery disease but also presents a clear avenue for translation into clinical practice. Future research is aimed at refining algorithms, validating findings across diverse populations, and integrating this approach into routine workflows. Determining how best to incorporate these measurements into clinical guidelines will be a key focus, as will exploring therapeutic implications and whether interventions targeting pericardial fat reduction can improve cardiovascular outcomes.

In essence, Mayo Clinic’s AI-driven quantification of pericardial adipose tissue signifies a paradigm shift from traditional risk models towards a more mechanistic and individualized understanding of cardiovascular risk. As heart disease continues to impose a heavy toll globally, innovations like this provide hope for more effective disease prevention through earlier detection and personalized care strategies delivered seamlessly within existing healthcare frameworks.

This study exemplifies the burgeoning potential of AI in medicine, where sophisticated computational models unlock unprecedented insights from standard diagnostic tools. Such advances herald a new era where the amalgamation of technology and medicine transcends previous limitations, driving forward the promise of next-generation precision cardiovascular care.

Subject of Research: Artificial intelligence-enhanced cardiovascular risk prediction using pericardial adipose tissue quantification in coronary artery calcium scans.

Article Title: Deep learning-derived pericardial adipose tissue by electrocardiogram-gated cardiac computed tomography predicts cardiovascular events beyond coronary calcium score

News Publication Date: 24-Mar-2026

Web References:
– American Journal of Preventive Cardiology publication: https://www.sciencedirect.com/science/article/pii/S2666667726001431
– Mayo Clinic AI in Cardiology program: https://www.mayoclinic.org/departments-centers/ai-cardiology/overview/ovc-20486648
– 2026 American College of Cardiology Scientific Session: https://accscientificsession.acc.org/

References:
Esmaeili, Z., Lopez-Jimenez, F., et al. (2026). Deep learning-derived pericardial adipose tissue by electrocardiogram-gated computed tomography predicts cardiovascular events beyond coronary calcium. American Journal of Preventive Cardiology.

Image Credits: Not provided.

Keywords

Artificial intelligence, Cardiovascular disease, Coronary artery calcium scoring, Pericardial adipose tissue, Cardiac computed tomography, Risk prediction, Deep learning, Precision medicine, Preventive cardiology, AI in healthcare, Cardiac imaging, Long-term cardiovascular risk